Quotient Therapeutics

News

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.